Compared with the validation cohort, the serum bilirubin (11.4 ± 5.0 vs.14.1 ± 7.7 μmol/L, P = 0.009), albumin (38.3 ± 5.1 vs. 40.2 ± 4.3 g/L, P = 0.008), neutrophil counts (3.5 ± 1.8 vs. 4.1 ± 2.2 × 109/L, P = 0.014), and tumor satellite nodules (11.3% vs. 24.6%, P = 0.007) in the training cohort were significantly lower. The gene discussed is ALB; the disease is neoplasm.